Nomenclature	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1398	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1400	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1401	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1402
Common abbreviation	NAPE‐PLD	FAAH	FAAH2	NAAA
HGNC, UniProt	https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:21683, http://www.uniprot.org/uniprot/Q6IQ20	https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:3553, http://www.uniprot.org/uniprot/O00519	https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:26440, http://www.uniprot.org/uniprot/Q6GMR7	https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:736, http://www.uniprot.org/uniprot/Q02083
EC number	–	http://www.genome.jp/dbget‐bin/www_bget?ec:3.5.1.99: anandamide + H2O <=> arachidonic acid + ethanolamine oleamide + H2O <=> oleic acid + NH3	http://www.genome.jp/dbget‐bin/www_bget?ec:3.5.1.99: anandamide + H2O <=> arachidonic acid + ethanolamine oleamide + H2O <=> oleic acid + NH3	http://www.genome.jp/dbget‐bin/www_bget?ec:3.5.1.‐
Rank order of affinity	–	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2364 > http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=284 > http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2661 > http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3622 [http://www.ncbi.nlm.nih.gov/pubmed/17015445?dopt=AbstractPlus]	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=284 > http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2661 > http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2364 > http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3622 [http://www.ncbi.nlm.nih.gov/pubmed/17015445?dopt=AbstractPlus]	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3622 > http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5221 > http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3621 ≥ http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2661 > http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2364 [http://www.ncbi.nlm.nih.gov/pubmed/11463796?dopt=AbstractPlus]
Selective inhibitors	–	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10248 (pIC50 8.4) [http://www.ncbi.nlm.nih.gov/pubmed/29017758?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5206 (pIC50 7.8) [http://www.ncbi.nlm.nih.gov/pubmed/18693015?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5244 (pIC50 6.3–7.8) [http://www.ncbi.nlm.nih.gov/pubmed/17949010?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5235 (pIC50 7.4) [http://www.ncbi.nlm.nih.gov/pubmed/17015445?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9944 (pIC50 7), http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4339 (pIC50 6.3–7) [http://www.ncbi.nlm.nih.gov/pubmed/17015445?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5243 (pIC50 6.6) [http://www.ncbi.nlm.nih.gov/pubmed/19389627?dopt=AbstractPlus]	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5235 (pIC50 7.9–8.4) [http://www.ncbi.nlm.nih.gov/pubmed/19095868?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/17015445?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4339 (pIC50 7.5–8.3) [http://www.ncbi.nlm.nih.gov/pubmed/19095868?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/17015445?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10248 (pIC50 7.2) [http://www.ncbi.nlm.nih.gov/pubmed/29017758?dopt=AbstractPlus]	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10121 (pIC50 8.1) [http://www.ncbi.nlm.nih.gov/pubmed/28802121?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/29572189?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9178 (Irreversible inhibition) (pIC50 7.6) [http://www.ncbi.nlm.nih.gov/pubmed/25874594?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6493 (pIC50 6.4) [http://www.ncbi.nlm.nih.gov/pubmed/19926854?dopt=AbstractPlus] – Rat, http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5161 (pIC50 5.3) [http://www.ncbi.nlm.nih.gov/pubmed/14686878?dopt=AbstractPlus]
Comments	NAPE‐PLD activity appears to be enhanced by polyamines in the physiological range [http://www.ncbi.nlm.nih.gov/pubmed/12047899?dopt=AbstractPlus], but fails to transphosphatidylate with alcohols [http://www.ncbi.nlm.nih.gov/pubmed/10428468?dopt=AbstractPlus] unlike phosphatidylcholine‐specific phospholipase D.	–	The FAAH2 gene is found in many primate genomes, marsupials, and other distantly related vertebrates, but not a variety of lower placental mammals, including mouse and rat [http://www.ncbi.nlm.nih.gov/pubmed/17015445?dopt=AbstractPlus].	–